Drug updated on 5/17/2024
Dosage Form | Capsule (oral; 40 mg, 60 mg, 80 mg) |
Drug Class | Vesicular monoamine transporter 2 inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adults with tardive dyskinesia.
- For the treatment of chorea associated with Huntington’s disease.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Valbenazine (Ingrezza) is indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease. It has been shown to be more effective than placebo in inducing a 'slight improvement' in psychosis symptoms without a significant difference from active comparators.
- Four systematic reviews/meta-analyses focused on the efficacy, safety, and subpopulation considerations of valbenazine as well as deutetrabenazine.
- Compared to traditional antipsychotics that induce dopamine receptor supersensitivity resulting in tardive dyskinesia, valbenazine may have antipsychotic activity with a potential reduced risk of this condition.
- Both valbenazine and deutetrabenazine demonstrated effectiveness in reducing tardive dyskinesia symptoms across various populations including an Asian cohort, suggesting their global applicability.
- These drugs exhibit favorable safety profiles characterized by low rates of serious adverse events such as QT prolongation, parkinsonism, suicidal ideation, or mortality, which underlines their tolerability, making them promising treatment options for tardive dyskinesia.
- Long-term studies indicate robust efficacy for valbenazine, making it a valuable option, while there is a need for more information on the long-term impact of deutetrabenazine.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Ingrezza (valbenazine) Prescribing Information. | 2023 | Neurocrine Biosciences, Inc., San Diego, CA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis. | 2024 | Psychopharmacology |
Comparative analysis of deutetrabenazine and valbenazine as VMAT2 inhibitors for tardive dyskinesia: a systematic review. | 2024 | Tremor and Other Hyperkinetic Movements |
Treatment recommendations for tardive dyskinesia. | 2019 | Canadian Journal of Psychiatry |
A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine. | 2019 | Therapeutic Advances in Psychopharmacology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia third edition. | 2021 | American Psychiatric Association |